\n\n\n\n\t\t\n\t\t\tValentis\n\t\t\thttp://www.valentis.com/\n\t\t
\n\t\t\n\t\t\tWatch Company\n\t\t\tGet Widget\n\t\t
\n\tValentis is a biotechnology company that was engaged in the development of innovative products for peripheral arterial disease (PAD), a large and unsatisfied market. On July 11, 2006 Valentis...More»
\n\t\t\tValentis is a biotechnology company that was engaged in the development of innovative products for peripheral arterial disease (PAD), a large and unsatisfied market. On July 11, 2006 Valentis announced that no statistically significant difference was seen in the primary endpoint or any of the secondary endpoints in its Phase IIb clinical trial of VLTS 934 in PAD. The primary efficacy endpoint in the study was improvement in exercise tolerance on an escalating grade treadmill after 90 days in patients receiving VLTS 934 versus patients receiving placebo. While Valentis focused its efforts on the development of novel peripheral arterial disease therapeutics, its technologies are being applied by its collaborators for the development of therapeutics to treat a variety of indications including infectious diseases and cancer.«Less
\n\n\t\t\tOverview
\n\t\t\t\tLocation: \tBurlingame, CA, United States\n
\n\t\t\t\tIndustry: Biopharmaceuticals
\n\t\t\t\tTags:\n\t\t\t\tbiotech,\n\t\t\t\tmedical study,\n\t\t\t\tdrug development,\n\t\t\t\tdead,\n\t\t\t\tUrigen Pharmaceuticals,\n\t\t\t\tValentis,\n\t\t\t\turigen\n\t\t\t\t
\n\t\t\t